Literature DB >> 26021840

Association Study of the TREM2 Gene and Identification of a Novel Variant in Exon 2 in Iranian Patients with Late-Onset Alzheimer's Disease.

Zohreh Mehrjoo1, Amin Najmabadi, Seyedeh Sedigheh Abedini, Marzieh Mohseni, Koorosh Kamali, Hossein Najmabadi, Hamid Reza Khorram Khorshid.   

Abstract

OBJECTIVE: To analyze the association between TREM2 exon 2 variants and late-onset (sporadic) Alzheimer's disease (AD) in an elderly Iranian population.
MATERIALS AND METHODS: Exon 2 of TREM2 in a total of 131 AD patients and 157 controls was genotyped using polymerase chain reaction and Sanger sequencing. Fisher's exact test was used to compare the allele and genotype frequency between the 2 study groups.
RESULTS: One homozygous and 2 heterozygous carriers of rs75932628-T in the AD patients and 1 heterozygous carrier in the control group were identified. One novel damaging variant, G55R, was also detected in the AD patient group. The frequency of rs75932628-T as well as the amount of rare variants were higher in the AD patients than in the controls, but this did not reach a statistically significant association with AD (odds ratio: 4.8; 95% confidence interval: 0.54 to 43.6; p = 0.270).
CONCLUSION: The rs75932628-T allele frequency in the elderly Iranian population (0.86%) was high.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26021840      PMCID: PMC5588241          DOI: 10.1159/000430842

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


Introduction

Dementia, a major disability in elderly people, is increasing in developing countries as a result of the demographic trend toward older age groups [1,2,3]. The most common form of dementia is Alzheimer's disease (AD) which is defined as a neurodegenerative disorder that affects memory, behavior, and thinking ability, and then impairs basic body movement, eventually leading to death [4]. AD usually begins to manifest around the age of 65 and affects half of the population aged ≥85 years in its late-onset form [5]. Aside from aging, family history and genetics also influence AD [4,5]. A number of studies have been performed on the genetic causes and risk factors of AD. Mutations in AβPP, PSEN1 and PSEN2 cause familial early-onset AD that typically begins before age 65 [2]. One of the most significant late-onset (sporadic) AD risk factors is allele Ԑ4 of the Apo E gene. Based on the estimations, 40-65% of AD patients possess 1 or 2 copies of the Apo EԐ4 gene [4]. Recent studies disclosed another significant AD risk factor, the rs75932628-T allele, with a significance similar to Apo EԐ4′s [6,7]. This allele is a rare nonsynonymous variant in exon 2 of triggering receptor expressed on the myeloid cells 2 gene (TREM2, OMIM 605086). This variant is predicted to cause R47H in the TREM2 IgV domain. Aside from rs75932628-T, the abundance of other variants in exon 2 of the TREM2 gene in AD patients versus the comparative lack of variants in healthy individuals was also reported to be significant [6]. The TREM2 protein takes part in innate immunity by its expression as a receptor on the surface of microglia, macrophages, osteoclasts, and monocyte-derived dendritic cells [8]. In the brain, the TREM2 protein participates in the phagocytosis of cell debris and apoptotic materials during anti-inflammatory processes [9]. Mutations in TREM2 have been reported in other diseases with early-onset dementia, for example in polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, frontotemporal dementia-like syndrome, and frontotemporal lobar degeneration [10,11,12]. So far, the association of TREM2 variants with AD has not been studied in the Iranian population. Hence, we performed this study to determine the abundance of rare variants in exon 2 of the TREM2 gene, including rs75932628-T, in AD patients and controls from 6 different ethnicities living in the Middle Eastern country Iran: Fars, Turk, Kurd, Lor, Gilak, and Mazani.

Subjects and Methods

Subjects

Blood samples from 131 late-onset (sporadic) AD patients (75 female and 56 male) were collected from Iran's Alzheimer's Association as well as from the Kahrizak, Mehrvarzan, and Farzanegan nursing homes from autumn of 2007 until summer 2008. The patients were diagnosed with AD by physicians according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria. The inclusion criteria were: age ≥ 65 years, absence of a familial history of AD, and having no other neurologic or psychiatric diseases. Blood samples from 157 controls (102 female, 55 male) were collected from the same nursing homes and the laboratory of the Rheumatology Center of Iran. The patients and controls were adjusted for age, sex, ethnicity, educational stages, and occupation. This study was approved by the Ethics Committee of Iran's Ministry of Health and Medical Education, and written informed consent was obtained from all of the patients and controls.

Molecular Genetic and Statistical Analysis

The DNA was extracted from the blood samples using the salting out method [13]. To genotype exon 2 of the TREM2 gene in patients and controls, primers were designed for this region using the Primer3Plus software [14]. The DNA samples were amplified by polymerase chain reaction, followed by Sanger sequencing. Then, the samples were analyzed with the CodonCode aligner software, version 4.0.4 (CodonCode Corp., Dedham, Mass., USA). The phenotypic effects of observed variants were predicted using the Polyphen2 software [15]. The statistical analyses were conducted with SPSS 11.5 (SPSS Inc., Chicago, Ill., USA). Fisher's exact test was used for the comparison of the allele and genotype frequencies between the 2 study groups. The χ2 test was used to compare the potential confounding variables age, sex, ethnicity, educational stages, and occupation between the patients and controls. Four patients and 5 controls were excluded from the analysis because their occupational data were not available. p values < 0.05 were assumed to be statistically significant.

Results

No significant differences were observed between the cases and controls in age, sex, ethnicity, educational stages, and occupation using the χ2 test (p > 0.05; table 1). One homozygous and 2 heterozygous carriers of rs75932628-T in AD patients and 1 heterozygous carrier in the control group were identified (table 2). This rare variant was identified in 2.29% of cases and 0.63% of controls, but it did not reach a statistically significant association with AD (odds ratio: 4.8; 95% confidence interval: 0.54 to 43.6; p = 0.270; table 2). Three more variants (p.R62H, p.R62C, and p.G55R) and 1 variant (p.A28V) were detected in AD patients and controls, respectively. The p.G55R with the ‘probably damaging′ predicted phenotype has not been reported before (table 2). The abundance of rare variants was higher in the AD patients than in the controls, but this did not show a statistically significant association with AD (odds ratio: 4.8; 95% confidence interval: 0.54 to 43.6; p = 0.270; table 2).
Table 1

Comparison of sex, educational stages, ethnicity, occupation, and mean age between AD patients and controls

Baseline characteristicsAD patients, nControls, np value
SexFemale75 (57.3)102 (65)0.180

Educational stagesIlliterate57 (43.5)64 (40.8)0.464
Primary school35 (26.7)53 (33.8)
High school15 (11.5)21 (13.4)
High school diploma16 (12.2)14 (8.9)
College or university8 (6.1)5 (3.2)

EthnicityFars83 (63.4)95 (60.5)0.806
Turk32 (24.4)42 (26.8)
Kurd5 (3.8)3 (1.9)
Lor2 (1.5)3 (1.9)
Gilak and Mazani9 (6.9)14 (8.9)

OccupationHousewife74 (58.3)87 (57.2)0.825
Self-employed26 (20.5)27 (17.8)
Worker13 (10.2)14 (9.2)
Farmer4 (3.1)7 (4.6)
Employee10 (7.9)17 (11.2)

Mean age ± SD, years77.6 ± 7.277.9 ± 7.50.669

Values in parentheses represent percentages.

Table 2

Variants found in exon 2 of TREM2 through Sanger sequencing in 131 AD patients and 157 controls

SNP No.PositionRef. geno-typeMutant geno-typeMutant genotypes, n
p valueOdds ratio (95% CI)Minor alleles, n
p valueOdds ratio (95% CI)Predicted proteinPoly-Phen2
in AD patientsin controlsin AD patientsin controls
rs7593262841129252CCTC210.8592.4(0.22 − 27.2)410.2704.8(0.54 − 43.6)R47HProbablydamaging
TT110.905undefined(1.000)

rs14333248441129207CCTC100.909undefined100.909undefinedR62HBenign(0.016)

rs20125831441129208GGAG100.909undefined100.909undefinedR62CProbablydamaging(0.999)

n.a.41129229CCTC100.909undefined100.909undefinedG55RProbablydamaging(0.884)

rs223425241129309GGAG011.000undefined011.0000A28VPossiblydamaging(0.503)

CI = Confidence interval; n.a = not available; SNP = single nucleotide polymorphism.

Discussion

Although more variants were observed in the AD patient population compared to the control group, neither the abundance of TREM2 rare variants nor the rs75932628-T variant showed a statistically significant association with AD. In our study, the 0.86% frequency of the rs75932628-T allele in the Iranian population was higher than the reported frequencies of this allele in other studied populations, which were 0.65% in Icelandic-origin [7], 0.3% in Spanish-origin [16], and 0.29% in European- or American-origin populations [17]. Previously, Jonsson et al. [7] and Guerreiro et al. [6] studied thousands of samples with European or North American descent and showed that rs75932628-T is a significant risk factor for AD in these populations. These findings were confirmed by other studies in Spanish, French, and American Caucasians [16,17,18]. In studies which showed that the rs-75932628-T variant was significantly associated with AD, the amounts of samples were higher than in our study, ranging from 3.65 to 28 times [6,16]. Therefore, considering the higher rate of rs75932628-T allele frequency in Iranian samples than that in previous studies, and also the higher prevalence of rs75932628-T allele in our AD patients than in the controls, increasing the sample size probably will reveal a significant result of association between the rs75932628-T allele and AD in the Iranian population. Replicating studies in Asian populations did not support a statistically significant association of TREM2 variants with AD [19,20,21,22]. Yu et al. [19] observed no rs75932628-T variants in thousands of AD patients and controls from a northern Han Chinese population. In the Japanese population, 1 out of 2,190 AD patients and 2 out of 2,498 controls were heterozygous carriers of rs75932628-T [21]. Accordingly, the rs75932628-T seems to be very rare in Eastern Asian population. Our results show that the Iranian population is more similar to the European than to the Eastern Asian population concerning the AD risk factor rs75932628-T allele. The limitation of this study is its small sample size which could account for the lack of statistical significance.

Conclusion

A high frequency (0.86%) of the rs-75932628-T allele was observed in Iranian-origin samples, but our results did not show a statistically significant difference between the AD patients and the controls.

Disclosure Statement

The authors have no conflicts of interest to declare.
  21 in total

1.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

2.  Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population.

Authors:  Akinori Miyashita; Yanan Wen; Nobutaka Kitamura; Etsuro Matsubara; Takeshi Kawarabayashi; Mikio Shoji; Naoki Tomita; Katsutoshi Furukawa; Hiroyuki Arai; Takashi Asada; Yasuo Harigaya; Masaki Ikeda; Masakuni Amari; Haruo Hanyu; Susumu Higuchi; Masatoyo Nishizawa; Masaichi Suga; Yasuhiro Kawase; Hiroyasu Akatsu; Masaki Imagawa; Tsuyoshi Hamaguchi; Masahito Yamada; Takashi Morihara; Masatoshi Takeda; Takeo Takao; Kenji Nakata; Ken Sasaki; Ken Watanabe; Kenji Nakashima; Katsuya Urakami; Terumi Ooya; Mitsuo Takahashi; Takefumi Yuzuriha; Kayoko Serikawa; Seishi Yoshimoto; Ryuji Nakagawa; Yuko Saito; Hiroyuki Hatsuta; Shigeo Murayama; Akiyoshi Kakita; Hitoshi Takahashi; Haruyasu Yamaguchi; Kohei Akazawa; Ichiro Kanazawa; Yasuo Ihara; Takeshi Ikeuchi; Ryozo Kuwano
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study.

Authors:  Josue D Gonzalez Murcia; Cameron Schmutz; Caitlin Munger; Ammon Perkes; Aaron Gustin; Michael Peterson; Mark T W Ebbert; Maria C Norton; Joann T Tschanz; Ronald G Munger; Christopher D Corcoran; John S K Kauwe
Journal:  Neurobiol Aging       Date:  2013-07-12       Impact factor: 4.673

4.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

5.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

6.  Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals.

Authors:  Jin-Tai Yu; Teng Jiang; Ying-Li Wang; Hui-Fu Wang; Wei Zhang; Nan Hu; Lin Tan; Lei Sun; Meng-Shan Tan; Xi-Chen Zhu; Lan Tan
Journal:  Neurobiol Aging       Date:  2013-10-11       Impact factor: 4.673

Review 7.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.

Authors:  Raj N Kalaria; Gladys E Maestre; Raul Arizaga; Robert P Friedland; Doug Galasko; Kathleen Hall; José A Luchsinger; Adesola Ogunniyi; Elaine K Perry; Felix Potocnik; Martin Prince; Robert Stewart; Anders Wimo; Zhen-Xin Zhang; Piero Antuono
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

8.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

9.  Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer's disease from mainland China.

Authors:  Bin Jiao; Xiaoyan Liu; Beisha Tang; Lihua Hou; Lin Zhou; Fufeng Zhang; Yafang Zhou; Jifeng Guo; Xinxiang Yan; Lu Shen
Journal:  Neurobiol Aging       Date:  2014-05-01       Impact factor: 4.673

10.  DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.

Authors:  Juha Paloneva; Jami Mandelin; Anna Kiialainen; Tom Bohling; Johannes Prudlo; Panu Hakola; Matti Haltia; Yrjo T Konttinen; Leena Peltonen
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  10 in total

Review 1.  Remembering your A, B, C's: Alzheimer's disease and ABCA1.

Authors:  Cutler T Lewandowski; Megan S Laham; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2022-01-24       Impact factor: 14.903

2.  Genetic Analysis of TREM2 Variants in Tunisian Patients with Alzheimer's Disease.

Authors:  Zied Landoulsi; Mouna Ben Djebara; Imen Kacem; Youssef Sidhom; Rym Kefi; Sonia Abdelhak; Amina Gargouri-Berrechid; Riadh Gouider
Journal:  Med Princ Pract       Date:  2018-05-03       Impact factor: 1.927

Review 3.  Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How.

Authors:  Cutler T Lewandowski; Juan Maldonado Weng; Mary Jo LaDu
Journal:  Neurobiol Dis       Date:  2020-02-20       Impact factor: 5.996

Review 4.  How understudied populations have contributed to our understanding of Alzheimer's disease genetics.

Authors:  Nadia Dehghani; Jose Bras; Rita Guerreiro
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

5.  TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.

Authors:  Jorge L Del-Aguila; Bruno A Benitez; Zeran Li; Umber Dube; Kathie A Mihindukulasuriya; John P Budde; Fabiana H G Farias; Maria Victoria Fernández; Laura Ibanez; Shan Jiang; Richard J Perrin; Nigel J Cairns; John C Morris; Oscar Harari; Carlos Cruchaga
Journal:  Mol Neurodegener       Date:  2019-05-08       Impact factor: 14.195

6.  Differential role of triggering receptors expressed on myeloid cells 2 R47H in 3 neurodegenerative diseases based on a systematic review and meta-analysis.

Authors:  Bin Zhang; Rui Li; Yufan Zhang; Xia Gao
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 7.  Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants.

Authors:  Julie Hoogmartens; Rita Cacace; Christine Van Broeckhoven
Journal:  Alzheimers Dement (Amst)       Date:  2021-02-20

8.  The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer's disease: A systematic review and meta-analysis.

Authors:  Rong Li; Xia Wang; Pengfei He
Journal:  Exp Ther Med       Date:  2021-02-11       Impact factor: 2.447

Review 9.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

10.  Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer's disease.

Authors:  Elham Mehdizadeh; Mohammad Khalaj-Kondori; Zeinab Shaghaghi-Tarakdari; Saeed Sadigh-Eteghad; Mahnaz Talebi; Sasan Andalib
Journal:  Bioimpacts       Date:  2019-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.